{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:05:37Z","timestamp":1787162737318,"version":"build-2736575974"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2013,1,30]],"date-time":"2013-01-30T00:00:00Z","timestamp":1359504000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0054522","type":"journal-article","created":{"date-parts":[[2013,1,30]],"date-time":"2013-01-30T17:28:25Z","timestamp":1359566905000},"page":"e54522","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":51,"title":["Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients"],"prefix":"10.1371","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct00321594","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ling-Zhi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Yi Michelle","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Win-Lwin","family":"Thuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Ying Amelia","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seow-Ching","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Li-Ann","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Kiat","family":"Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Chin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"How-Sung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Ansher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Ratain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon-Cher","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,1,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0065-230X(04)91004-4","article-title":"Histone deacetylase inhibitors","volume":"91","author":"PA Marks","year":"2004","journal-title":"Adv Cancer Res"},{"key":"ref2","first-page":"773","article-title":"Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines","volume":"24","author":"SG Gray","year":"2004","journal-title":"Int J Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1073\/pnas.2536759100","article-title":"Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications","volume":"101","author":"CS Mitsiades","year":"2004","journal-title":"Proc Natl Acad Sci"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1073\/pnas.0500369102","article-title":"Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors","volume":"102","author":"MJ Peart","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1586\/era.10.230","article-title":"Potential of histone deacetylase inhibitors for bladder cancer treatment","volume":"1","author":"N Tanji","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2217\/epi.09.38","article-title":"Modulation of gene expression in ovarian cancer by active and repressive histone marks","volume":"2","author":"SA Bapat","year":"2010","journal-title":"Epigenomics"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-08-2788","article-title":"Epigenetic modifiers: basic understanding and clinical development","volume":"15","author":"RL Piekarz","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref8","first-page":"5827","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood","volume":"117","author":"RL Piekarz","year":"2011"},{"key":"ref9","first-page":"1247","article-title":"FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma. The Oncologist","volume":"12","author":"BS Mann","year":"2007"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1586\/era.11.4","article-title":"New drug therapies in peripheral T-cell lymphoma","volume":"11","author":"RA Howman","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","article-title":"A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors","volume":"14","author":"NL Steele","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00280-010-1495-6","article-title":"The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in <italic>in vitro<\/italic> and <italic>in vivo<\/italic> colon cancer models","volume":"68","author":"YS Na","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/JTO.0b013e318191520c","article-title":"Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma","volume":"4","author":"SS Ramalingam","year":"2009","journal-title":"J Thorac Oncol"},{"key":"ref14","first-page":"275","article-title":"The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol","volume":"60","author":"A Tumber","year":"2007"},{"key":"ref15","first-page":"222","article-title":"Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbation in NF-\u03baB and Bim. Br J Haematol","volume":"152(2)","author":"Y Dai","year":"2011"},{"key":"ref16","first-page":"2052","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol","volume":"29","author":"G Giaccone","year":"2011"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00277-011-1240-1","article-title":"Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)","volume":"91(1)","author":"A Cashen","year":"2012","journal-title":"Ann Hematol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.ejca.2010.02.047","article-title":"Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours","volume":"46","author":"HJ Mackay","year":"2010","journal-title":"Eur J Cancer"},{"key":"ref19","first-page":"638","article-title":"A pharmacogenetic study of vorinostat glucuronidation. Pharmacogenet","volume":"20","author":"SP Kang","year":"2010","journal-title":"Genomics"},{"key":"ref20","first-page":"760","article-title":"Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer. Pharmacogenet","volume":"21(11)","author":"NS Wong","year":"2011","journal-title":"Genomics"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.2549","article-title":"Elucidation of the metabolic and elimination pathways of panobinostat (LBH589) using [<sup>14<\/sup>C]-panobinostat","volume":"27","author":"S Clive","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref22","first-page":"124","article-title":"Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull","volume":"28","author":"T Shiraga","year":"2005"},{"key":"ref23","first-page":"2981","article-title":"Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Res","volume":"69","author":"RM Balliet","year":"2009"},{"key":"ref24","first-page":"2409","article-title":"A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients. J Chromatogr B Biomed Sci Appl","volume":"878","author":"LZ Wang","year":"2010"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0009-9236(99)70078-0","article-title":"Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism","volume":"65","author":"L Iyer","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/FPC.0b013e3280121fe9","article-title":"UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers","volume":"17","author":"AL Yoder Graber","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01213011-200505000-00004","article-title":"Haplotypes of variants in the UDP-glucuronosyltransferase 1A9 and 1A1 genes","volume":"15","author":"F Innocenti","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"ref28","first-page":"3069","article-title":"Glucuronidation of N-hydroxy metabolits of N-acetylbenzidine. Carcinogenesis","volume":"16","author":"SR Babu","year":"1995"},{"key":"ref29","first-page":"1963","article-title":"Glucuronidation of benzidine and its metabolites by cDNA-expressed human UDP-glucuronosyltransferases and pH stability of glucuronides. Carcinogenesis","volume":"20","author":"C Marco","year":"1999"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/rcm.1984","article-title":"High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum","volume":"19","author":"LH Du","year":"2005","journal-title":"Rapid Commun Mass Spectrom"},{"key":"ref31","first-page":"1759","article-title":"Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab Dispos","volume":"37","author":"T Izukawa","year":"2009"},{"key":"ref32","first-page":"8719","article-title":"Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem","volume":"273","author":"CP Strassburg","year":"1998"},{"key":"ref33","first-page":"3361","article-title":"Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I\/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol","volume":"30","author":"W Yeo","year":"2012"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM199511023331802","article-title":"The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert\u2019s syndrome","volume":"333","author":"PJ Bosma","year":"1995","journal-title":"N Engl J Med"},{"key":"ref35","first-page":"1382","article-title":"Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol","volume":"22","author":"F Innocenti","year":"2004"},{"key":"ref36","first-page":"1290","article-title":"UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst","volume":"99","author":"JM Hoskins","year":"2007"},{"key":"ref37","first-page":"8170","article-title":"Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A","volume":"95","author":"E Beutler","year":"1998"}],"updated-by":[{"DOI":"10.1371\/annotation\/df796504-a2ea-4807-a412-85985bb2550b","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,1,13]],"date-time":"2014-01-13T00:00:00Z","timestamp":1389571200000}}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0054522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T20:18:31Z","timestamp":1644178711000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0054522"}},"subtitle":[],"editor":[{"given":"John","family":"Luk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,30]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0054522","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717985121.793472616","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,30]]}}}